Gilead Sciences (GILD) 'Crushed' the Quarter, Piper Jaffray Says; Remains Top Large-Cap Biotech Pick
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Gilead Sciences (GILD) Bullish Stance Reiterated at BMO Capital Amid 'Strong' Q1
May 1, 2015 7:00 AM EDTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and $159 price target on Gilead Sciences (NASDAQ: GILD) following "strong" Q1 results after the close with room to expand in HCV.
Birchenough commented, "We are maintaining our Outperform rating on the shares of GILD... More
Gilead Sciences (GILD) Bullish Stance Reiterated at Baird on 'Beat and Raise' Q1
May 1, 2015 6:42 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $126 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and raise' Q1.
Skorney commented, "A sizeable beat should be enough to support the stock and perhaps stop the sector slide. We expect... More
Gilead Sciences (GILD) Tops Q1 EPS by 48c, Raises FY Revenue Guidance
April 30, 2015 4:02 PM EDTGilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.76, $0.48 better than the analyst estimate of $2.28. Revenue for the quarter came in at $7.59 billion versus the consensus estimate of $6.81 billion.
Gilead Sciences sees FY2015 revenue of $28-29 million, versus the consensus of $28.50... More
